title: Current concepts on pathophysiology, diagnosis and treatment of diffuse oesophageal spasm.
abstract: Diffuse oesophageal spasm is a functional oesophageal motility disorder of unknown aetiology, which appears to be due to a disturbance of the normal pharmacological timing of propulsive contraction occurring in the oesophageal body after swallowing. The lack of pathophysiological understanding may be due to the fact that there is more than one pathophysiological pathway causing symptoms of diffuse oesophageal spasm. Barium studies, oesophageal scintigraphy and fiberoptic examination can be helpful in finding the correct diagnosis, but manometry is still the gold standard of diagnostic procedures. Similar to other spastic oesophageal motility disorders, pharmacological treatment of diffuse oesophageal spasm includes nitrates, calcium antagonists, anticholinergics and antidepressants with varying beneficial effects. Botulinum toxin, which provides sufficient treatment as measured by symptom score and manometric patterns in patients with achalasia, was recently evaluated for the treatment of diffuse oesophageal spasm in small patient selections with promising results.
authors.affiliation: Department of Internal Medicine II, Technical University of Munich, Germany. martin.storr@lrz.tum.de
authors.forename: M
authors.initials: M
authors.lastname: Storr
authors.forename: H D
authors.initials: HD
authors.lastname: Allescher
authors.forename: M
authors.initials: M
authors.lastname: Classen
mesh_terms: D001676:Biofeedback, Psychology; D001905:Botulinum Toxins / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D015155:Esophageal Spasm, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D008365:Manometry; D010276:Parasympatholytics / Q000627:therapeutic use*; D004561:Transcutaneous Electric Nerve Stimulation
chemical_list: D002121:Calcium Channel Blockers; D010276:Parasympatholytics; D001905:Botulinum Toxins